Ardelyx Inc. (Nasdaq: ARDX) reported positive results from a Phase 3 study of tenapanor to treat irritable bowel syndrome with constipation sending the stock price soaring $2.40 to close at $7.80.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|